Reduced reproductive capability in men presenting an unexplained (unidentified) abnormal semen analysis Urological and Genital Diseases
Conditions
Interventions
A total of 299 participants who met the inclusion criteria were invited to participate. Participant number 1 was allocated to group 1, participant number 2 to group 2, participant number 3 to group 1
Profertil®, Lenus Pharma GmbH, Vienna, Austria)
Semen analysis was performed at baseline and after three months of treatment.
Sponsors
Karl Landsteiner Institute of Cell-Based Treatment in Gynecology (Karl Landsteiner Institut für zellorientierte Therapie in der Gynäkologie)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Male 2. 20 to 60 years of age 3. Suffering from at least one year of subfertility 4. At least one recent pathological semen analysis result
Exclusion criteria
Exclusion criteria: 1. Azoospermia 2. Aspermia 3. Varicocele 4. Recent urogenital infections 5. Hormonal disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following sperm parameters were analysed at baseline and after 3 months of treatment: 1. Sperm volume (ml) 2. Sperm density (mio/ml) 3. Overall, fast and slow progressive motility (expressed as %) 4. % of sperm with normal morphology All parameters were defined according to WHO guidelines (4th edition). Sperm analysis was performed with an automatic, computer analysing system called Sperm Class Analyzer® CASA System, by MICROPTIC SL, company based in Barcelona, Spain. | — |
Countries
Austria
Contacts
Public ContactMarkus Lipovac
Outcome results
None listed